Kevin Michael Krause - Jan 9, 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Strategy Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Kevin Michael Krause
Stock symbol
ANTX
Transactions as of
Jan 9, 2024
Transactions value $
-$115,352
Form type
4
Date filed
1/11/2024, 07:59 PM
Previous filing
Jan 4, 2024
Next filing
Mar 18, 2024

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Options Exercise $0 -2.42K -4.62% $0.00 49.9K Jan 9, 2024 Common Stock 2.42K $0.42 Direct F1, F3
transaction ANTX Stock Option (right to buy) Options Exercise $0 -5K -15.71% $0.00 26.8K Jan 9, 2024 Common Stock 5K $6.60 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.
F2 Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.33. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3 The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020 and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.
F4 The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date.